Visiomed Group SA
PAR:ALVMG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.1646
0.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Visiomed Group SA
Visiomed Group SA
Total Equity
Visiomed Group SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Visiomed Group SA
PAR:ALVMG
|
Total Equity
€24.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
132%
|
CAGR 10-Years
16%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Total Equity
€56.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
20%
|
|
|
Biomerieux SA
PAR:BIM
|
Total Equity
€3.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Carmat SA
PAR:ALCAR
|
Total Equity
-€22.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
Biosynex SA
PAR:ALBIO
|
Total Equity
€103.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
40%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Total Equity
€95.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Visiomed Group SA
Glance View
Visiomed Group SA engages in the development and distribution of healthcare products and services. The company is headquartered in Puteaux, Ile-De-France. The company went IPO on 2011-07-05. The firm is primarily engaged in the design, manufacture and marketing of medical electronics. The company develops and markets health products in the fields of medical and well-being self-diagnosis to provide non-drug prevention and treatment solutions. The firm's product portfolio comprises MyThermo, an infrared contact-less medical thermometer; MyTension, an automatic blood pressure and pulse monitors; MyOxy, a finger pulse oximeter; MyECG, a pocket electrodiogram; MyGluco, a blood sugar meter; My Coach, a health and fitness coach, and Epiderm, a telemedicine dermatology mobile application, among others. The firm serves pharmacies, health professionals, hospitals, clinics and retirement homes. The company also offers connected solutions and COVID devices such as deconfinement kits, masks, filter cushion, serological tests etc. The Company’s subsidiaries include ThermoFlash and BewellConnect.
See Also
What is Visiomed Group SA's Total Equity?
Total Equity
24.1m
EUR
Based on the financial report for Dec 31, 2023, Visiomed Group SA's Total Equity amounts to 24.1m EUR.
What is Visiomed Group SA's Total Equity growth rate?
Total Equity CAGR 10Y
16%
Over the last year, the Total Equity growth was -1%.
You don't have any saved screeners yet
